Management of androgenetic alopecia

Antonella Tosti, F. Camacho-Martinez, R. Dawber

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50. Methods This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women. Results The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women. Conclusions Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.

Original languageEnglish
Pages (from-to)205-214
Number of pages10
JournalJournal of the European Academy of Dermatology and Venereology
Volume12
Issue number3
StatePublished - Dec 1 1999
Externally publishedYes

Fingerprint

Alopecia
Minoxidil
Finasteride
Hair
Ovarian Diseases
Miniaturization
Cyproterone Acetate
Hyperandrogenism
Androgen Antagonists
Spironolactone
Scalp
Physical Examination
Disease Progression
Therapeutics
Guidelines

Keywords

  • 5α-reductase
  • Alopecia
  • Androgens
  • Finasteride
  • Minoxidil

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Management of androgenetic alopecia. / Tosti, Antonella; Camacho-Martinez, F.; Dawber, R.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 12, No. 3, 01.12.1999, p. 205-214.

Research output: Contribution to journalArticle

Tosti, A, Camacho-Martinez, F & Dawber, R 1999, 'Management of androgenetic alopecia', Journal of the European Academy of Dermatology and Venereology, vol. 12, no. 3, pp. 205-214.
Tosti, Antonella ; Camacho-Martinez, F. ; Dawber, R. / Management of androgenetic alopecia. In: Journal of the European Academy of Dermatology and Venereology. 1999 ; Vol. 12, No. 3. pp. 205-214.
@article{73bdaa1098fa468b93b58934fb78f8a3,
title = "Management of androgenetic alopecia",
abstract = "Background Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50{\%} of men and 40{\%} of women by the age of 50. Methods This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women. Results The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66{\%} of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women. Conclusions Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.",
keywords = "5α-reductase, Alopecia, Androgens, Finasteride, Minoxidil",
author = "Antonella Tosti and F. Camacho-Martinez and R. Dawber",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "12",
pages = "205--214",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Management of androgenetic alopecia

AU - Tosti, Antonella

AU - Camacho-Martinez, F.

AU - Dawber, R.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Background Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50. Methods This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women. Results The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women. Conclusions Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.

AB - Background Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50. Methods This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women. Results The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women. Conclusions Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.

KW - 5α-reductase

KW - Alopecia

KW - Androgens

KW - Finasteride

KW - Minoxidil

UR - http://www.scopus.com/inward/record.url?scp=0033127976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033127976&partnerID=8YFLogxK

M3 - Article

C2 - 10461639

AN - SCOPUS:0033127976

VL - 12

SP - 205

EP - 214

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 3

ER -